MiCo BioMed USA
Private Company
Funding information not available
Overview
MiCo BioMed USA is a private, commercial-stage diagnostics company leveraging its proprietary Optimiser™ microfluidic technology to enhance immunoassay performance across multiple settings, from point-of-care to automated labs. The company offers an open-source platform that allows for the transfer of existing ELISA protocols with minimal reagent changes, claiming significant improvements in sensitivity, speed, and sample volume. With over 70 assays validated on its platform and products commercially available for the life science market, MiCo is seeking strategic partnerships to expand into the clinical diagnostics sector. Its strategy targets cost-sensitive and throughput-constrained segments of the global diagnostics market.
Technology Platform
Optimiser™ microfluidic technology for immunoassays, enabling seamless transfer of ELISA protocols, tunable sensitivity, low sample volumes, and improved throughput on open-source POC and automated lab systems.
Opportunities
Risk Factors
Competitive Landscape
MiCo competes in the microfluidic immunoassay space against large diversified players like Abbott (i-STAT), Roche (cobas), and QuidelOrtho, as well as specialized POCT companies. Its open-source approach differentiates it from typically closed proprietary systems but requires convincing partners to adopt its platform over developing proprietary solutions or partnering with larger competitors.